Serum Institute Of India

The agreement positions the Pune-based vaccine maker to manufacture the M72/AS01E TB vaccine candidate at scale if ongoing Phase III trials succeed and approvals are secured

Adar Poonawalla confirms he will submit a strong and competitive bid for Royal Challengers Bengaluru, following USL's strategic review of the IPL team

CSIR-IGIB and Serum Institute of India have partnered to transfer indigenous CRISPR-based technology that could cut sickle cell gene therapy costs from crores to a fraction

ICMR-Aiims studies found no link between Covid-19 vaccines and sudden deaths in adults; heart issues, genetics, and lifestyle factors were identified as primary causes, not vaccination

Serum Institute and DNDi sign MoU to develop and scale a dengue monoclonal antibody vaccine with Phase 3 trials in India, Brazil and other endemic countries

Bavarian Nordic will transfer the technology of the current manufacturing process to SII to enable supply for the Indian market, the company said in a statement on Monday

Bavarian Nordic has partnered with the Serum Institute of India to produce its Mpox vaccine for the Indian market and expand global capacity through contract manufacturing

Pneumococcal vaccines address infections caused by pneumococcal bacteria, including pneumonia, meningitis, and blood infections, collectively known as invasive pneumococcal disease

In a landmark deal that has captured the attention of Bollywood and the business world alike, Adar Poonawalla has surpassed industry giants Reliance and Saregama

Adar Poonawalla's Serene Entertainment has acquired a 50 per cent stake in Dharma for Rs 1,000 crore

Mpox cases have been confirmed among children and adults in more than a dozen African countries, and a new form of the virus is spreading

The standalone property, spanning approximately 30,000 sq ft., joins a prestigious collection of mansions in the area that are typically priced between Rs 400-750 crore.

Mankind Pharma rose as much as 1.2 per cent following Thursday's Bloomberg News report. The shares are up about 6.5 per cent this year and 10 per cent in the past 12 months

A new high efficacy malaria vaccine co-developed by the Serum Institute of India (SII) and the University of Oxford was officially rolled out on Monday when Cote d'Ivoire in West Africa became the first country to begin administering R21/Matrix-M. The vaccine, which was granted World Health Organisation (WHO) approval last year, is said to have undergone a rigorous regulatory process and clinical assessment and was found to be highly effective and affordable. As a low-dose vaccine, it can be manufactured at speed and scale which is seen as critical to stemming the spread of the mosquito-borne disease. Reducing the malaria burden is finally within sight. Today's start of the R21/Matrix-M vaccine roll-out marks a monumental milestone after years of incredible work with our partners at Oxford and Novavax, said SII CEO Adar Poonawalla. At Serum, we believe that it is every person's right to have access to affordable and essential disease prevention. That's why we have committed to ...

The world's largest vaccine maker currently has the capacity to produce 3 billion doses of all types of vaccines each year, but only sells about 1.5 billion doses annually

The vaccine has been developed in collaboration with the University of Oxford and Novavax's Matrix-M adjuvant

India currently does not have any XBB 1.5 variant-based vaccines in the market

The collaboration leverages SII's manufacturing and distribution strength with IntegriMedical's innovative technology

AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India

Serum Institute of India says it stopped manufacturing Covishield since December 2021